Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:51 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pazopanib Maintenance Phase II
NCT02207309 · Ludwig-Maximilians - University of Munich · PHASE2 · terminated · last registry update 2024-08-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “poor recruitment” | – | Registry record, Ludwig-Maximilians - University of Munich |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-08-06Results posted on the registry: Hitendra Patel, Gemcitabine + Nivolumab 10 MG/ML Intravenous Solution [OPDIVO] (NCT03697564)
- 2025-05-02Results posted on the registry: M.D. Anderson Cancer Center, Pazopanib Hydrochloride (NCT01436227)
- 2025-04-30Also stopped (terminated): University of Washington, Sirolimus Albumin-bound Nanoparticles + Pazopanib hydrochloride (NCT03660930)
- 2025-03-21Results posted on the registry: Gulam Manji, PLX3397 + sirolimus (NCT02584647)
- 2025-03-21Also stopped (terminated): Gulam Manji, PLX3397 + sirolimus (NCT02584647)
- 2025-03-19Results posted on the registry: National Cancer Institute (NCI), Sunitinib (NCT06390826)
- 2025-03-07Also stopped (terminated): Aptose Biosciences Inc., CG-806 (NCT04477291)
- 2025-03-03Results posted on the registry: Daiichi Sankyo Co., Ltd., Pexidartinib (NCT04703322)
- 2025-02-14Also stopped (terminated): AIO-Studien-gGmbH, a drug against CSF1R (NCT03013946)
- 2025-02-14Results posted on the registry: Cogent Biosciences, Inc., CGT9486 + Pexidartinib (NCT02401815)
- 2025-02-12Phase 3 first posted: Incyte Corporation, INCA034176 + Best Available Therapy (BAT) (NCT06821542)
- 2025-02-12Also stopped (terminated): Georgetown University, sunitinib and capecitabine (NCT00961571)
- 2025-01-27Results posted on the registry: M.D. Anderson Cancer Center, Abiraterone Acetate + Prednisone (NCT01254864)
- 2025-01-15Results posted on the registry: Zai Lab (Shanghai) Co., Ltd., Ripretinib + Sunitinib (NCT04633122)
- 2024-12-30Results posted on the registry: Daiichi Sankyo, Pexidartinib (NCT04526704)
- 2024-12-10Phase 3 first posted: Sun Yat-sen University, axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib (NCT06726421)
- 2024-11-27Results posted on the registry: Syndax Pharmaceuticals, axatilimab (NCT03604692)
- 2024-10-29Results posted on the registry: Pfizer, Avelumab (MSB0010718C) + Axitinib (AG-013736) (NCT02684006)
- 2024-10-17Results posted on the registry: University Health Network, Toronto, Sunitinib (NCT00843037)
- 2024-10-10Results posted on the registry: Syndax Pharmaceuticals, Axatilimab (NCT04710576)
- 2024-09-19Phase 3 first posted: Incyte Corporation, INCA034176 + Placebo (NCT06585774)
- 2024-09-19Results posted on the registry: National Cancer Institute (NCI), Cediranib + Sunitinib (NCT01391962)
- 2024-09-19Results posted on the registry: M.D. Anderson Cancer Center, Quizartinib + Venetoclax (NCT03735875)
- 2024-09-19Also stopped (terminated): M.D. Anderson Cancer Center, Quizartinib + Venetoclax (NCT03735875)
- 2024-08-29Phase 3 first posted: Daiichi Sankyo, Quizartinib + Placebo (NCT06578247)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision